Our proprietary LentiPeak lentiviral vector platform offers: - Serum-free, transient transfection, HEK293 based process
- Third-generation LV plasmid system
- High functional titers ranging from 1x10^8 to 1x10^9 TU/mL
- Proven platform performance with various CAR and TCR constructs at multiple production scales
- Integrated analytical support with panels of established testing methods in-house
- Efficient supply chain management and risk mitigation
- Streamlined Tech Transfer between PD and cGMP manufacturing with aligned unit operations, equipment, bill of materials and analytics
- Pre-established cGMP documentation and trained technical team
- Available cGMP capacity without waiting time
- Comprehensive regulatory support package
- Parallel development with cell processing activities for ex-vivo programs
Our LentiPeak platform can support your program development by:
- Accelerating development timelines
- Reducing development costs and cost of goods
- Lowering manufacturing cost of goods with increased process yield
- Ensuring process comparability between early-stage and pivotal trials
- De-risking vector production upfront
- Meeting specific development program needs through a fully customizable platform